# Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

> **NCT00071539** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Recurrent Glioblastoma Multiforme

## Interventions

- **DRUG:** TP-38
- **DRUG:** TP38

## Key facts

- **NCT ID:** NCT00071539
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-01
- **Final completion:** 2006-07
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071539, "Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00071539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*